Myoderm, a global clinical trial supply company, announced that effective July 1, 2019, Michael Cohen, currently chief executive officer, will transition to executive chairman of the company and James Lovett, the current chief operating officer, will assume the role of chief executive officer and will report to Michael. In addition, Myoderm’s president Robby Cohen will also take on the role of co-chairman.     The moves are the result of the company’s growth in recent years. Under Michael’s lead...